Company news
Immuron Limited (ASX:IMC) news
Every Immuron Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Immuron to launch PROIBS® in the United States
September 4, 2026
PROIBS US Distribution Agreement
September 3, 2026
Immuron Reports FY26 Preliminary Results
August 28, 2026
FY26 Results Presentation
August 27, 2026
IMC Rare Earths Ltd Announces Closing of $20 Million Initial Public Offering
July 30, 2026
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
July 20, 2026
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
July 16, 2026
Immuron FY26 Sales Update
July 15, 2026
Immuron Double Digit 3Q Sales Growth
April 17, 2026
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
March 5, 2026
Strategic Update and HY26 Results
February 25, 2026
Immuron Reports HY26 Results and Strategic Reset
February 25, 2026
Appendix 4D and Half Year Report
February 25, 2026
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
January 21, 2026
Immuron Reports Continued Sales Growth
January 19, 2026
Uniformed Services University to Release Topline Data
December 9, 2025
Immuron New U.S. Department of Defense Award & Clinical Trial Update
December 3, 2025
Immuron IMM-529 IND approved by FDA
November 5, 2025
IMM-529 IND approved by FDA
November 5, 2025
Immuron Announces Clinical Trial Update
October 31, 2025
Clinical Trial Update
October 30, 2025
Immuron launch PROIBS for IBS
October 23, 2025
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
October 21, 2025
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
October 17, 2025
Immuron Q1 FY26 YoY growth
October 13, 2025
Immuron Submits IMM-529 IND to FDA
October 8, 2025
Immuron Letter to Shareholders – Projects Update
October 2, 2025
FY25 Results Presentation
August 28, 2025
Appendix 4E Preliminary Final Report
August 28, 2025
Immuron partners with InvestorHub
August 26, 2025
Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
August 20, 2025
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
August 19, 2025
Immuron - FY25 global sales exceed projection, up 49% on prior year
July 17, 2025
FY25 global sales exceed projection, up 49% on prior year
July 16, 2025
Immuron Travelan® highest sales in history
April 10, 2025
Immuron Travelan highest sales in history
April 10, 2025
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
March 5, 2025
IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
March 4, 2025
Immuron Travelan continued strong sales growth
January 16, 2025
Immuron Announces Travelan Clinical Trial Update
January 14, 2025
NMRC Reports Results for Campylobacter Clinical Study
October 4, 2024
Trading Halt
October 2, 2024
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 5, 2024
Appendix 4E and Preliminary Final Report
August 30, 2024
Immuron Travelan record sales globally, Australia and USA
July 14, 2024
IMM-529 pre-IND FDA filing
July 1, 2024
Immuron Travelan sales continued strong growth
April 9, 2024
Travelan to progress to Phase 3 Clinical Trials in the US
March 6, 2024
Immuron achieves record Travelan sales
February 12, 2024
Immuron achieves record half yearly Travelan sales
January 15, 2024